Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L E Friberg

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|December 6, 2013
PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GISTE K Hansson, G Ma, M A Amantea, et al.
Cancer Letters|January 9, 2001
In vivo activity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patientsE Jonsson, L E Friberg, M O Karlsson, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 9, 2014
A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysisB Ribba, N H Holford, P Magni, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 22, 2013
PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GISTE K Hansson, M A Amantea, P Westwood, et al.
Clinical Pharmacology and Therapeutics|February 12, 2015
Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunitiesK Venkatakrishnan, L E Friberg, D Ouellet, et al.
Antimicrobial Agents and Chemotherapy|May 13, 2009
Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteriaD Plachouras, M Karvanen, L E Friberg, et al.
Clinical Pharmacology and Therapeutics|December 23, 2006
Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter proteinF A de Jong, T J Scott-Horton, D L Kroetz, et al.
The Pharmacogenomics Journal|April 7, 2010
Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancerT K Bergmann, C Brasch-Andersen, H Gréen, et al.
Intensive Care Medicine|April 15, 2017
The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infectionsT Tängdén, V Ramos Martín, T W Felton, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 28, 2020
Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteriaA N Kristoffersson, V Rognås, M J E Brill, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
CPT: Pharmacometrics & Systems Pharmacology|December 6, 2013
PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GISTE K Hansson, G Ma, M A Amantea, et al.
Cancer Letters|January 9, 2001
In vivo activity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patientsE Jonsson, L E Friberg, M O Karlsson, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 9, 2014
A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysisB Ribba, N H Holford, P Magni, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 22, 2013
PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GISTE K Hansson, M A Amantea, P Westwood, et al.
Clinical Pharmacology and Therapeutics|February 12, 2015
Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunitiesK Venkatakrishnan, L E Friberg, D Ouellet, et al.
Antimicrobial Agents and Chemotherapy|May 13, 2009
Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteriaD Plachouras, M Karvanen, L E Friberg, et al.
Clinical Pharmacology and Therapeutics|December 23, 2006
Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter proteinF A de Jong, T J Scott-Horton, D L Kroetz, et al.
The Pharmacogenomics Journal|April 7, 2010
Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancerT K Bergmann, C Brasch-Andersen, H Gréen, et al.
Intensive Care Medicine|April 15, 2017
The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infectionsT Tängdén, V Ramos Martín, T W Felton, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 28, 2020
Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteriaA N Kristoffersson, V Rognås, M J E Brill, et al.
Pageof 4